Evidence map›Paper›PMID 40547077›Full record

ReviewMultiple sclerosis journal - experimental, translational and clinical

A review of the validation of the Brief Cognitive Assessment for Multiple Sclerosis in Latin America.

Miriam E Jiménez-Maldonado, Edgar R Valdivia-Tangarife, Miguel Ángel Macías-Islas, Fernando Cortés-Enríquez, Alejandra Morlett-Paredes, Fabiola Gonzalez-Ponce, Mario A Mireles-Ramírez, Jazmin Marquez-Pedroza, Nayeli A Sánchez-Rosales, Jorge I Gámez-Nava and 2 more

Abstract readReview
In one paragraph

Review in Multiple sclerosis journal - experimental, translational and clinical. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Miriam E Jiménez-MaldonadoDepartamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.
Edgar R Valdivia-TangarifeDepartamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.ORCID https://orcid.org/0000-0002-0936-7525
Miguel Ángel Macías-IslasDepartamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.
Fernando Cortés-EnríquezDepartamento de Neurología, Hospital General, No. 14 del Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.
Alejandra Morlett-ParedesDepartamento de Neurociencias, Universidad de California San Diego, La Jolla, CA, USA.
Fabiola Gonzalez-PonceInstituto de Terapéutica Experimental y Clínica, Departamento de Fisiologia, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.
Mario A Mireles-RamírezDepartamento de Neurología, Unidad de Alta Especialidad Médica, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.
Jazmin Marquez-PedrozaDivision de Neurociencias, Centro de Investigacion Biomedica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.ORCID https://orcid.org/0000-0003-2859-726X
Nayeli A Sánchez-RosalesDepartamento de Neurología, Unidad de Alta Especialidad Médica, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.
Jorge I Gámez-NavaPrograma de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.
Laura González-LópezPrograma de Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.
Teresita Villaseñor-CabreraDepartamento de Neurociencias, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México.ORCID https://orcid.org/0000-0001-5403-436X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The present review aimed to identify published studies that reported the validation of the Brief Cognitive Assessment for Multiple Sclerosis (BICAMS) in Latin America (LATAM). Methods: To compile a comprehensive list of available validation studies, we performed a systematic review of the literature via an electronic search of PubMed and Web of Science via the keywords "Validation," "Brief Cognitive Assessment for Multiple Sclerosis," "BICAMS," and "Latin America." Results: Twenty-seven sources of validation studies for the BICAMS were identified. Of the 27 citations identified, only four provide validation of the BICAMS in LATAM. These studies include a comparison of cognitive performance between multiple sclerosis (MS) patients and healthy controls (HCs) across all three BICAMS tests. Overall, the studies included a greater proportion of patients with RRMS and middle-aged adults and included participants with wide ranges of education levels. Conclusion: We provide a detailed description of the BICAMS validation currently available for people living in LATAM. Although the validation of tests in diverse populations has gained interest in the field, there is still a need for more studies among people from LATAM countries.

Indexed as

BICAMSLatin Americamultiple sclerosisReviewvalidation studies

Identifiers

PMID40547077
PMCPMC12179470

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.